Biotechs: Are they set for a renaissance after Ox Glyco manages RECORD cash call

Hi Meg and Chadd - should have known I'd touch a nerve with folks who are invested in PRM! The main point I wanted to make is that Proteome seem to have very few (1 or 2?)specialists making investment decisions. OGS are in similar business but with greater resource. I had my name on at least 30 patents years ago, only one led to a product.
Meg, I didn't mean standard unit trusts, but classy biotech specialist investment trusts. Check out the chart for IBT and you'll see it is possible to make pretty spectacular gains with a diversified biotech fund that is well managed. But everything said, best of luck with PRM - I hope it makes you a bomb! Cheers